Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 10;19(12):3978.
doi: 10.3390/ijms19123978.

The Epigenetic Regulation of HCC Metastasis

Tae-Su Han  1 , Hyun Seung Ban  2 , Keun Hur  3 , Hyun-Soo Cho  4
Affiliations
Review

The Epigenetic Regulation of HCC Metastasis

Tae-Su Han et al. Int J Mol Sci. .

Abstract

Epigenetic alterations, such as histone modification, DNA methylation, and miRNA-mediated processes, are critically associated with various mechanisms of proliferation and metastasis in several types of cancer. To overcome the side effects and limited effectiveness of drugs for cancer treatment, there is a continuous need for the identification of more effective drug targets and the execution of mechanism of action (MOA) studies. Recently, epigenetic modifiers have been recognized as important therapeutic targets for hepatocellular carcinoma (HCC) based on their reported abilities to suppress HCC metastasis and proliferation in both in vivo and in vitro studies. Therefore, here, we introduce epigenetic modifiers and alterations related to HCC metastasis and proliferation, and their molecular mechanisms in HCC metastasis. The existing data suggest that the study of epigenetic modifiers is important for the development of specific inhibitors and diagnostic targets for HCC treatment.

Keywords: DNA methylation; HCC; epigenetics; histone methylation; metastasis; miRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Summary for epigenetic regulation in HCC metastasis.
See this image and copyright information in PMC

References

    1. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999;340:745–750. doi: 10.1056/NEJM199903113401001. - DOI - PubMed
    1. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917. doi: 10.1016/S0140-6736(03)14964-1. - DOI - PubMed
    1. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008;359:378–390. doi: 10.1056/NEJMoa0708857. - DOI - PubMed
    1. Chen J., Jin R., Zhao J., Liu J., Ying H., Yan H., Zhou S., Liang Y., Huang D., Liang X., et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 2015;367:1–11. doi: 10.1016/j.canlet.2015.06.019. - DOI - PubMed
    1. Hardy T., Mann D.A. Epigenetics in liver disease: From biology to therapeutics. Gut. 2016;65:1895–1905. doi: 10.1136/gutjnl-2015-311292. - DOI - PMC - PubMed